lifestyle.entreprenerd.net

Author: InflaRx N.V.

InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting

March 18, 2026
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

March 13, 2026
InflaRx to Report Full Year 2025 Results on March 19, 2026

March 12, 2026